patient
|
month
| | | | | | | | | | |
---|
no.
|
1
|
2
|
3
|
4
|
5
|
6
|
7
|
8
|
9
|
10
|
11
|
4
|
U3,0%
| | | |
(2,8%/0%)
| | | | | | |
15
|
U1,7%
|
U1,7%
|
U1,7%
|
U1,7%
|
U1,7%
| | | |
U2,3%
| | |
30
| | | | |
U2,1%
| |
3,5%
| |
(1,5%/90%)
|
U0,9%
|
U0,9%
|
32
|
U2,4%
|
U1,7%
|
(0,2%/100%)
| |
U2,1%
|
U2,6%
|
U2,2%
|
U2,2%
|
U2,1%
| |
U2,2%
|
37
|
(0,2%/100%)
|
U1,2%
|
U1,3%
|
U1,4%
|
2,5%
|
39%
| |
U1,1%
| |
+
| |
38
|
(0,4%/25%)
|
U0,9%
|
U0,9%
|
U1,2%
|
U1,1%
|
U0,9%
| |
U0,9%
|
U1,2%
| |
U0,9%
|
39
|
U2,7%
| | | |
(0,1%/100%)
| | | |
U1,7%
|
(0,2%/50%)
|
U2,6%
|
43
|
(0,8%/100%)
|
(6%/0%)
|
64%
|
+
| | | | | | | |
48
|
U1,7%
|
U1,7%
|
(0,3%/100%)
|
U1,7%
|
U1,7%
| | | |
U1,7%
| |
U2,4%
|
patient
|
month
| | | | | | | | | | |
no.
|
12
|
13
|
14
|
15
|
16
|
17
|
18
|
19
|
20
|
21
|
22
|
4
| | | | | | | |
+
| | | |
15
|
(3,3%/0%)
|
U2,2%
|
U1,7%
| |
U1,7%
|
U1,7%
| |
U1,7%
|
U1,7%
|
U1,7%
| |
30
|
U1,5%
|
U1,5%
| | | |
U1,5%
|
U1,5%
| |
U1,4%
|
U1,5%
|
U1,3%
|
32
|
U1,7%
| |
U2,2%
| | | | |
U2,2%
|
U2,2%
| | |
37
| | | | | | | | | | | |
38
|
U1,3%
| |
U0,9%
|
U1,3%
|
U1,2%
|
U1,2%
| |
U1,3%
|
U1,2%
| | |
39
| |
U2,6%
|
U2,5%
| | |
U2,4%
| | | | |
U2,5%
|
43
| | | | | | | | | | | |
48
|
U1,7%
| | | |
U2,2%
| | | | | | |
patient
| | | | | | | | | | | |
no.
|
23
|
24*/25
|
26
|
28
|
29*/30
|
32
|
33
|
35
|
38*/39
|
48
| |
4
| | | | | | | | | | | |
15
| |
U2,2%*
| | |
U2,2%*
| |
U2,2%
| | | | |
30
|
U1,3%
|
U0,9%
|
U0,9%
|
U1,3%
| |
+
| | | | | |
32
| |
U0,9%*
| | | | | | | | | |
37
| | | | | | | | | | | |
38
|
U1,1%
| |
U1,1%
| |
U1,1%
| |
U1,1%
|
U1,3%
|
U1,2%*
| | |
39
| | | |
U2,5%
| | |
U2,3%
| |
U1,7%
|
U2,2%
| |
43
| | | | | | | | | | | |
48
| | | | | | | | | | | |
- UX% = under cut off level of X%, in brakets are samples were simultaneous hybrization of gonosomes and disease-marker probes was applied, first percentage = amount of residual cells, second percentage = fraction of disease-marker positive residual cells.